Drug Profile
Research programme: adeno-associated virus gene therapy - Kings College London/Pfizer
Alternative Names: AAV gene therapy - Kings College London/PfizerLatest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Kings College London
- Developer Alcyone Therapeutics; Kings College London; Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inborn genetic disorders; Neurodegenerative disorders
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in USA (Intrathecal)
- 22 Jun 2021 Alcyone Lifesciences is now called Alcyone Therapeutics
- 28 Feb 2020 No recent reports of development identified for preclinical development in Inborn genetic disorders in United Kingdom